It can happen even after a mild case and at any age, although rates have declined since the pandemic’s early years. Studies show vaccination can lower the risk. It also is not clear what causes long ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its ...

The world’s second-richest person launched the Courage and Civility Award in 2021 to support philanthropists—and Eva Longoria ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...